source
- AI drug hunter Enveda raises $311M for late-stage obesity, inflammatory disease pushTech darling Enveda has raised a total of $845 million in the past six years. The latest funding round is intended to pave the way for an IPO someday.
- Immunovant halts lupus program after Phase 2b trial fails to meet efficacy endpointsImmunovant announced that its anti‑FcRn drug imeroprubart (IMVT‑1402) did not achieve the primary endpoint in a Phase 2b study in patients with cutaneous lupus erythematosus. The double‑blind tria…